Encorium Group, Inc. Announces $3.0 Million in New Contracts for Clinical Trials in Women’s Health

WAYNE, Pa.--(BUSINESS WIRE)--Encorium Group, Inc. (Nasdaq: ENCO), a leader in the design, development, and management of complex clinical trials and patient registries for many of the world's leading pharmaceutical and biotechnology companies, today announced that it has recently signed two new clinical trial contracts for Women’s Health indications. The aggregate value of the contracts is approximately $3.0 million. The trials, which represent repeat business for Encorium with a US based biotechnology company, will be conducted in Europe. Encorium will provide multiple services including project management, site management and monitoring, data management, biostatistical support, and medical writing. Revenue recognition will begin during the current third quarter and continue on a proportional performance basis over the life of the contract as services are performed.
MORE ON THIS TOPIC